On Monday, Jan. 7, Michael Lavery at Piper Sandler initiated coverage of the beverage giant, with an overweight rating and a ...

TD Cowen analyst Phil Nadeau maintained a Buy rating on Rhythm Pharmaceuticals (RYTM – Research Report) today. The company’s shares opened ...

Lisa Thomas, Managing Director and Deputy Head of Global Research at TD Cowen, discusses some of the key findings of a new TD Cowen report on the big investment themes of 2025, including shifting ...

TD Cowen analyst Andrew Kligerman maintained a Buy rating on Abacus Life (ABL – Research Report) today and set a price target of $14.00. The ...

El Lilly’s blockbuster weight-loss drug Zepbound is now eligible for coverage under Medicare prescription drug plans, when ...

TD Cowen has recently reiterated Marathon Petroleum Corp (MPC) stock to Buy rating, as announced on December 10, 2024, according to Finviz. Earlier, on November 6, 2024, TD Cowen had reiterated the ...

When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...

Investment analysts at TD Cowen began coverage on shares of CG Oncology (NASDAQ:CGON – Get Free Report) in a research report issued to clients and investors on Tuesday, MarketBeat.com reports. The ...

Fintel reports that on January 8, 2025, TD Cowen upgraded their outlook for Coca-Cola (NYSE:KO) from Hold to Buy. Analyst ...

Fintel reports that on January 8, 2025, TD Cowen downgraded their outlook for Leidos Holdings (NYSE:LDOS) from Buy to Hold.

“Two-thousand-twenty-four was a tough year for staples stocks, and 2025 is shaping up to be even tougher,” says TD Cowen ...

After a turbulent year, things should calm for payers with the advent of a business-friendly Trump administration — though ...